AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19953227 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg cortisol
Number of subjects: 30
Study 18155965 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cognitive rehabilitation
Number of subjects: 112
Study 18155965 — intervention group
Group type: COMPARATOR
Intervention: No postoperative cognitive rehabilitation (Control)
Number of subjects: 112
Study 15706008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-rich diet (800 mg/d cholesterol)
Number of subjects: 21
Study 15706008 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (250 mg/d cholesterol)
Number of subjects: 21
Study 12856482 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous digoxin synthesis
Number of subjects: 0
Study 12856482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolichol levels
Number of subjects: 0
Study 12856482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinone levels
Number of subjects: 0
Study 12856482 — intervention group
Group type: EXPERIMENTAL
Intervention: Free radical levels
Number of subjects: 0
Study 12856482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan catabolites
Number of subjects: 0
Study 12856482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine catabolites
Number of subjects: 0
Study 12856482 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous morphine synthesis
Number of subjects: 0
Study 12856482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol:phospholipid ratio
Number of subjects: 0
Study 12856482 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoconjugate levels of RBC membrane
Number of subjects: 0
Study 12856482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemispheric dominance
Number of subjects: 0
Study 10099861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (dose gradually increased in steps of 25 mg up to 100 mg per day)
Number of subjects: 15
Study 10099861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 15
Study 8733086 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg.kg‐1)
Number of subjects: 20
Study 8733086 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 1751665 — intervention group
Group type: EXPERIMENTAL
Intervention: AST‐120 (oral adsorbent composed of spherical porous carbon particles)
Number of subjects: 0
Study 1751665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 312708 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (2 mg/kg)
Number of subjects: 16
Study 312708 — intervention group
Group type: EXPERIMENTAL
Intervention: halothane
Number of subjects: 16
Study 30852783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) with human-assisted social robot
Number of subjects: 14
Study 30852783 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT) without human-assisted social robot
Number of subjects: 14
Study 31154895 — intervention group
Group type: EXPERIMENTAL
Intervention: Free play
Number of subjects: 197
Study 31154895 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed activity
Number of subjects: 197
Study 31154895 — intervention group
Group type: COMPARATOR
Intervention: Organized sessions
Number of subjects: 197
Study 27768857 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D3
Number of subjects: 448
Study 25927723 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/d for 60 days)
Number of subjects: 44
Study 25927723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23250357 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 38
Study 23250357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 21266377 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment for 32 weeks
Number of subjects: 78
Study 21266377 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 32 weeks
Number of subjects: 78
Study 19960133 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 19960133 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 17942341 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Ketac‐Endo/cold lateral compaction (group 8)
Number of subjects: 156
Study 17942341 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/AH Plus/cold lateral compaction (group 7)
Number of subjects: 156
Study 17942341 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta‐percha, Epiphany/cold lateral compaction (group 3)
Number of subjects: 156
Study 17942341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Endo with gutta‐percha (group 2)
Number of subjects: 156
Study 17942341 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta‐percha/Epiphany (group 3)
Number of subjects: 156
Study 15236107 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual endothelial cell enumeration
Number of subjects: 35
Study 15236107 — intervention group
Group type: COMPARATOR
Intervention: Automatic endothelial cell enumeration using NAVIS(R) system
Number of subjects: 35
Study 11524896 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions
Number of subjects: 0
Study 11524896 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacological interventions
Number of subjects: 0
Study 11524896 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 0
Study 11524896 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 0
Study 9502182 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rh-GH) 0.5-1.0 UIday(−1) s.c. at bed-time for 6 months
Number of subjects: 25
Study 9502182 — intervention group
Group type: COMPARATOR
Intervention: placebo for 6 months
Number of subjects: 25
Study 9502182 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rh-GH)
Number of subjects: 25
Study 9502182 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 8063979 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic‐interpersonal therapy
Number of subjects: 0
Study 8063979 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐behavioral therapy
Number of subjects: 0
Study 3175393 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive agents
Number of subjects: 0
Study 3175393 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 4689832 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 0
Study 4689832 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 0
Study 31982288 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 25 mg/day
Number of subjects: 346
Study 31982288 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 50 mg/day
Number of subjects: 346
Study 31982288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 30987269 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 blockade therapies
Number of subjects: 0
Study 30987269 — intervention group
Group type: EXPERIMENTAL
Intervention: Glial cell expression of PD-L1
Number of subjects: 0
Study 29161286 — intervention group
Group type: COMPARATOR
Intervention: Control (Glasses prescription only)
Number of subjects: 882
Study 29161286 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Glasses
Number of subjects: 882
Study 29161286 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Glasses + $15 Upgrade
Number of subjects: 882
Study 29161286 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Glasses + $30 Upgrade
Number of subjects: 882
Study 25091163 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (30 cm segment)
Number of subjects: 20
Study 23283526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1,000 mg plus pazopanib 400 mg (Cohort 1)
Number of subjects: 190
Study 23283526 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib 1,500 mg monotherapy (Cohort 1)
Number of subjects: 190
Study 23283526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1,500 mg plus pazopanib 800 mg (Cohort 2)
Number of subjects: 190
Study 21195327 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanoplasty with mastoidectomy (Group A)
Number of subjects: 62
Study 21195327 — intervention group
Group type: COMPARATOR
Intervention: Tympanoplasty without mastoidectomy (Group B)
Number of subjects: 62
Study 18983661 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acetaminophen (6 g daily for 3 days), started within 12 hours after symptom onset
Number of subjects: 0
Study 18983661 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study 17598572 — intervention group
Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser
Number of subjects: 25
Study 15033498 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational booklet, self-help workbook, brief group CBT over a 9-month period
Number of subjects: 117
Study 15033498 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational booklet, self-help workbook, brief group CBT
Number of subjects: 117
Study 15033498 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic scale based on simple additive scoring
Number of subjects: 117
Study 15033498 — intervention group
Group type: COMPARATOR
Intervention: Baseline severity measures
Number of subjects: 117
Study 11245505 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicinal herbs (CMH)
Number of subjects: 55
Study 11245505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 10193219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.05 mg.kg‐1
Number of subjects: 0
Study 10193219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg.kg‐1
Number of subjects: 0
Study 10193219 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.5 mg.kg‐1
Number of subjects: 0
Study 10193219 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium 0.15 mg.kg‐1
Number of subjects: 0
Study 10193219 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.08 mg.kg‐1
Number of subjects: 0
Study 10193219 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg.kg‐1
Number of subjects: 0
Study 8090943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifiers
Number of subjects: 60
Study 8090943 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocking
Number of subjects: 60
Study 8090943 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study 2903955 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular users of NSAIDs (12 patients)
Number of subjects: 75
Study 2903955 — intervention group
Group type: COMPARATOR
Intervention: Non-regular users of NSAIDs (63 patients)
Number of subjects: 75
Study 31420647 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200,000 IU initial dose followed by 100,000 IU monthly, n = 2558)
Number of subjects: 5110
Study 31420647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 2552)
Number of subjects: 5110
Study 31420647 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 5110
Study 31420647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study 31399140 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention (Prevent 2nd Stroke - P2S)
Number of subjects: 530
Study 31399140 — intervention group
Group type: COMPARATOR
Intervention: Minimal care control group (email with Internet addresses of generic health sites)
Number of subjects: 530
Study 29574292 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded insurance coverage
Number of subjects: 3121
Study 29574292 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based provider payments to improve quality
Number of subjects: 3121
Study 26935961 — intervention group
Group type: COMPARATOR
Intervention: Standard CVCs
Number of subjects: 1859
Study 26935961 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic CVCs
Number of subjects: 1859
Study 26935961 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin CVCs
Number of subjects: 1859
Study 25205139 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₃ (cholecalciferol 4,000 IU)
Number of subjects: 0
Study 25205139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22429970 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope® with Magill forceps
Number of subjects: 28
Study 22429970 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope® with Sponge forceps
Number of subjects: 28
Study 22429970 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 28
Study 19296055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (healthy school food policy)
Number of subjects: 1063
Study 19296055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1063
Study 17303041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 21
Study 17303041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 21
Study 17303041 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% ointment
Number of subjects: 21
Study 17303041 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 0.1% ointment
Number of subjects: 21
Study 17303041 — intervention group
Group type: COMPARATOR
Intervention: Control preparations (Vanicream and petrolatum)
Number of subjects: 21
Study 16244540 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 93
Study 16244540 — intervention group
Group type: COMPARATOR
Intervention: Mechanical stapling
Number of subjects: 93
Study 12049861 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (cisplatin 80 mg/m² by infusion over 4 h plus fluorouracil 1000 mg/m² daily by continuous infusion for 4 days) followed by surgical resection (CS group, n=400)
Number of subjects: 802
Study 12049861 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection alone (S group, n=402)
Number of subjects: 802
Study 9807602 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (manual lung hyperinflation and postural drainage)
Number of subjects: 46
Study 9807602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physiotherapy)
Number of subjects: 46
Study 9807602 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 9807602 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 46
Study 9807602 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 8129118 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 mg.kg‐1)
Number of subjects: 8
Study 8129118 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg.kg‐1)
Number of subjects: 8
Study 8129118 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (300 micrograms) after midazolam
Number of subjects: 8
Study 2530251 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 25 mg daily
Number of subjects: 15
Study 2530251 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 50 mg daily
Number of subjects: 15
Study 2530251 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 25 to 75 mg daily during open study
Number of subjects: 15
Study 2530251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30722719 — intervention group
Group type: EXPERIMENTAL
Intervention: Playground spaces that protect students from traffic
Number of subjects: 0
Study 30722719 — intervention group
Group type: EXPERIMENTAL
Intervention: Playgrounds exposed to full sun
Number of subjects: 0
Study 30722719 — intervention group
Group type: EXPERIMENTAL
Intervention: Unitary surface materials
Number of subjects: 0
Study 30722719 — intervention group
Group type: EXPERIMENTAL
Intervention: Loose fill surfacing materials
Number of subjects: 0
Study 30722719 — intervention group
Group type: EXPERIMENTAL
Intervention: Unitary surfaces
Number of subjects: 0
Study 30722719 — intervention group
Group type: EXPERIMENTAL
Intervention: Playground equipment with loose strings or ropes
Number of subjects: 0
Study 31697384 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04‐HPV‐16/18 vaccine
Number of subjects: 12550
Study 31697384 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12550
Study 28350578 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-creation intervention package
Number of subjects: 10219
Study 28350578 — intervention group
Group type: COMPARATOR
Intervention: Standard VMMC outreach alone (Control)
Number of subjects: 10219
Study 26164769 — intervention group
Group type: EXPERIMENTAL
Intervention: SS + SUF
Number of subjects: 1096
Study 26164769 — intervention group
Group type: COMPARATOR
Intervention: 3WSC
Number of subjects: 1096
Study 23249256 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive self-ligating brackets
Number of subjects: 46
Study 23249256 — intervention group
Group type: EXPERIMENTAL
Intervention: Active self-ligating brackets
Number of subjects: 46
Study 22015342 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair yoga
Number of subjects: 0
Study 22015342 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 0
Study 22015342 — intervention group
Group type: COMPARATOR
Intervention: Educational program
Number of subjects: 0
Study 18755830 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for place of care
Number of subjects: 71
Study 18755830 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for place of death
Number of subjects: 71
Study 18755830 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between patient and caregiver preferences for place of care
Number of subjects: 71
Study 18755830 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between patient and caregiver preferences for place of death
Number of subjects: 71
Study 18755830 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual place of death vs. preferences
Number of subjects: 71
Study 17144438 — intervention group
Group type: EXPERIMENTAL
Intervention: MetaKenkoh game (Intervention Group - IG)
Number of subjects: 77
Study 17144438 — intervention group
Group type: COMPARATOR
Intervention: Monitoring only (Control Group - CG)
Number of subjects: 77
Study 12680738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (blood concentrations of approximately 80‐100 mg/100 ml)
Number of subjects: 16
Study 12680738 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 16
Study 12680738 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 16
Study 12680738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 16
Study 10731530 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (125 micrograms/kg i.v. bolus)
Number of subjects: 32
Study 10731530 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg p.o.)
Number of subjects: 32
Study 9013372 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole-intolerant group
Number of subjects: 18
Study 9013372 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole-tolerant group
Number of subjects: 18
Study 1364856 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether plus mefloquine
Number of subjects: 35
Study 1364856 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 35
Study 2410328 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA‐AMP 10 mg/kg/day given as intramuscular injections 12 hours apart for five days followed by 5 mg/kg/day for 23 days
Number of subjects: 29
Study 2410328 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 29
Study 30531676 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 100
Study 30531676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 100
Study 30531676 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) and Sufentanil
Number of subjects: 100
Study 26926681 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² IV on day 1 of a 3-week cycle (arm A)
Number of subjects: 140
Study 26926681 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² IV plus ramucirumab 10 mg/kg IV on day 1 of a 3-week cycle (arm B)
Number of subjects: 140
Study 26926681 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² IV on day 1 plus icrucumab 12 mg/kg IV on days 1 and 8 of a 3-week cycle (arm C)
Number of subjects: 140
Study 24621807 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0
Study 22357725 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 20 g protein/d (20% pea, 20% soy, 30% egg, and 30% milk-protein isolate)
Number of subjects: 99
Study 22357725 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 20 g protein/d
Number of subjects: 99
Study 22357725 — intervention group
Group type: COMPARATOR
Intervention: 3 × 20 g maltodextrin/d
Number of subjects: 99
Study 20535042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus position after caudal epidural injection (Group 1, n=28)
Number of subjects: 57
Study 20535042 — intervention group
Group type: COMPARATOR
Intervention: Supine position after caudal epidural injection (Group 2, n=29)
Number of subjects: 57
Study 18473409 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (0.8 g/d) plus mesalamine (2.4 g/d)
Number of subjects: 37
Study 18473409 — intervention group
Group type: COMPARATOR
Intervention: mesalamine plus placebo
Number of subjects: 37
Study 15723220 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone (treatment A)
Number of subjects: 11
Study 15723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel with aprepitant (treatment B)
Number of subjects: 11
Study 12706636 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin-sodium
Number of subjects: 76
Study 12706636 — intervention group
Group type: COMPARATOR
Intervention: UFH/OA
Number of subjects: 76